Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products.

Raising Awareness to Mitigate the Risk for Patients and Added Scientific Value of Hemocompatibility Analysis As outlined earlier, a worrying trend is seen in the multiple recent (2010 onwards) clinical case reports of adverse events and even suspected lethal cases related to thromboembolic complications upon systemic infusion of highly procoagulant TF/CD142 expressing MSC products in patients. 12 , 19 While some well-respected academic center

also in 642 other papers